WO2002040031A1 - Preparation adhesive contenant estradiol - Google Patents

Preparation adhesive contenant estradiol Download PDF

Info

Publication number
WO2002040031A1
WO2002040031A1 PCT/JP2001/009915 JP0109915W WO0240031A1 WO 2002040031 A1 WO2002040031 A1 WO 2002040031A1 JP 0109915 W JP0109915 W JP 0109915W WO 0240031 A1 WO0240031 A1 WO 0240031A1
Authority
WO
WIPO (PCT)
Prior art keywords
patch
estradiol
drug
sensitive adhesive
liquid
Prior art date
Application number
PCT/JP2001/009915
Other languages
English (en)
Japanese (ja)
Inventor
Susumu Maruo
Hiroyuki Waseda
Nobuaki Hanajima
Original Assignee
Teijin Limited
Teysan Pharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Limited, Teysan Pharmaceuticals Co., Ltd. filed Critical Teijin Limited
Priority to KR10-2003-7006318A priority Critical patent/KR100533493B1/ko
Priority to JP2002542404A priority patent/JP3935839B2/ja
Priority to AU2002212763A priority patent/AU2002212763A1/en
Publication of WO2002040031A1 publication Critical patent/WO2002040031A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Definitions

  • the present invention relates to a patch containing extradiol. Background art
  • the estrogen, estradiol is also disclosed in, for example, Japanese Patent Application Publication No. 3-520925 and Japanese Patent Application Publication No. 6-5303756, in which Absorption enhancers have been proposed to improve the absorption.
  • Absorption enhancers have been proposed to improve the absorption.
  • An object of the present invention is to provide a patch which is excellent in skin permeability of estradiol, maintains the skin permeability for a long time, and is excellent in safety and economy.
  • the present inventors have conducted intensive studies to achieve such an object, and have found that a specific absorption promoter is used in a patch provided with an adhesive layer containing estradiol, an absorption accelerator, and an adhesive. As a result, it has been found that the object of the present invention is achieved, and the present invention has been completed. Disclosure of the invention
  • the present invention provides a patch in which an adhesive layer containing a drug, an absorption promoter and an adhesive is provided on one surface of a flexible support,
  • the drug is estradiol
  • the absorption enhancer comprises at least one selected from sorbitan monolaurate and polyethylene glycol monolaurate, and at least one selected from higher fatty acid esters and hydrocarbons which are liquid at room temperature;
  • the pressure-sensitive adhesive is an acrylic pressure-sensitive adhesive
  • the absorption promoter used in the present invention is selected from sorbitan monolaurate and polyethylene glycol monolaurate-and one selected from higher fatty acid esters and hydrocarbons which are liquid at room temperature. It is important that this is a mixture of the above. Only when this mixture is used, it is possible to obtain a patch having excellent transdermal absorbability and long-lasting skin permeability of estradiol.
  • the absorption promoter is at least one selected from sorbitan monolaurate and polyethylene glycol monolaurate, a patch having the above properties cannot be obtained. Similarly, even when only one or more selected from higher fatty acid esters and hydrocarbons which are liquid at room temperature, such patches cannot be obtained.
  • At least one selected from higher fatty acid esters and hydrocarbons which are liquid at room temperature is preferably a mixture of higher fatty acid esters and hydrocarbons. This is because it is effective not only in improving and sustaining the absorption of estradiol, but also in terms of skin adhesion and economics.
  • the mixing ratio is preferably 0.1: 0.9 force, and 0.8: 0.2.
  • the absorption enhancer of the present invention is preferably sorbitan monolaurate from the viewpoints of improving the absorption of estradiol, continuously improving the absorption, adhesion to the skin, economy, and water resistance to bathing. It is particularly preferred that the mixture is a mixture of carboxylic acids, higher fatty acid esters, and hydrocarbons.
  • Examples include isopropyl succinate, isopropyl palmitate, isostearyl palmitate, ethyl oleate, oleyl oleate, decyl oleate, getyl sebacate, and hexyl laurate.
  • isopropyl myristate, isopropyl palmitate, or ethyl oleate are preferred from the viewpoints of improving the absorption of estradiol, maintaining the effect over a long period of time, and irritating the skin.
  • isopropyl myristate can be mentioned as a particularly preferred one.
  • hydrocarbons according to the present invention examples include liquid paraffin, squalane, squalene, gelled hydrocarbons, and petrolatum. Liquid paraffin and / or squalane are preferred from the viewpoints of improvement, sustained absorption, economy and adhesive strength.
  • the content of one or more selected from sorbitan monolaurate and polyethylene glycol monolaurate in the pressure-sensitive adhesive layer is preferably 2 wt% or more and 10 wt% or less.
  • the content is less than 2 wt%, it is difficult to improve the sufficient skin permeability of the drug, and when the content exceeds 1 wt%, the effect of improving the skin permeability of the drug is leveled off. Therefore, it is not preferable in terms of safety and economy.
  • the content in one or more pressure-sensitive adhesive layers selected from higher fatty acid esters and hydrocarbons which are liquid at room temperature is preferably 5 wt% or more and 35 wt% or less. If the content is less than 5 wt%, it is difficult to maintain sufficient skin permeability of the drug and long-term skin permeability. On the other hand, if it exceeds 35 wt%, the effect of improving the skin permeability of the drug is improved. As the fruits peak, they are less favorable from an economic point of view. In addition, when the patch is applied to the skin and peeled off, glue residue easily forms on the skin.
  • the acryl-based pressure-sensitive adhesive in the present invention contains an alkyl (meth) acrylate having 2 to 20 carbon atoms as a main component, and has an (meth) acrylate of 10% or less. ) Acrylic acid-containing (meth) alkyl acrylate copolymers are preferred.
  • the alkyl (meth) acrylate having 2 to 20 carbon atoms include ethyl (meth) acrylate, butyl (meth) acrylate, and pentyl (meta).
  • (meth) alkyl acrylate means an alkyl acrylate or an alkyl methacrylate.
  • an acrylic adhesive may be mixed with a vinyl acetate adhesive or a silicone adhesive in an amount less than the equivalent amount of the acrylic adhesive.
  • estradiol of the present invention refers to natural estrogen, synthetic estrogen, and derivatives thereof, for example, estradiol benzoate, estradiol benzoate, estradiol dipropionate, Estradiol valerate, ethynyl estradiol, and the like. Among them, estradiol is preferred.
  • the content of the estradionil of the present invention in the patch is preferably 0.4 wt% or more and 2.5 wt% or less, particularly preferably 0.6 wt% or more and 2.01% or less. . If the content is less than 0.4 wt%, it is difficult to obtain a sufficient amount of the drug through the skin. On the other hand, if the content exceeds 2.5 wt%, it is uneconomical because the amount of residual drug in the patch after use increases.
  • a conventionally known method can be employed as a method for incorporating a drug into the pressure-sensitive adhesive layer.
  • a method for incorporating a drug into the pressure-sensitive adhesive layer a conventionally known method can be employed.
  • a method in which a drug solution is preliminarily mixed with a solution-type pressure-sensitive adhesive to form a drug-containing pressure-sensitive adhesive layer, or a pressure-sensitive adhesive layer that does not contain a drug or does not sufficiently contain a drug is impregnated, inverted, or This is a method in which the drug is contained in a sufficient amount for transdermal absorption by wearing or spraying.
  • Crosslinking may be performed in the pressure-sensitive adhesive layer of the present invention for the purpose of improving the cohesive strength of the pressure-sensitive adhesive layer.
  • a cross-linking method include cross-linking by ultraviolet rays or ultraviolet rays, or the use of a polymer such as a caustic anhydride, a polyisocyanate compound, an organic metal salt, a metal chelate compound, or a polymer capable of forming a polyion complex.
  • a method of adding a crosslinking agent to perform crosslinking can be used.
  • stabilizers such as magnesium stearate, zinc stearate, and citric anhydride; for example, ascorbic acid, toco acetate Antioxidants such as ferol and vitamin E; fragrances such as menthol, potato fulness, oil, lemon oil; preservatives such as dibutylhydroxytoluene and isobutyl paraoxybenzoate;
  • pH adjusters such as sodium citrate, sodium dihydrogen citrate, sodium hydrogen phosphite, sodium hydrogen phosphite and the like can be mentioned. These can be used alone or in combination of one or more.
  • the support used in the present invention is not particularly limited as long as it can adhere an adhesive layer and has a self-shape retention property.
  • the material and shape are not particularly limited. Absent.
  • polymer films such as polyester, polyolefin, polyvinyl chloride, polyurethane, and cellulose ester; fibers such as polyester, polyolefin, polyurethane, cellulose ester, and polyamide.
  • the thickness of the support is not particularly limited, but is preferably 50 to 100 m from the viewpoint of handleability.
  • the thickness of the pressure-sensitive adhesive layer in the present invention is not particularly limited, but is preferably from 10 to 300 m, and particularly preferably from 40 to 200 m.
  • sorbitan monolaurate and polyethylene are used as absorption accelerators.
  • Polyacrylic acid alkyl ester copolymer solution consisting of 90% 2-ethylhexyl acrylate, 7% methyl methacrylate, and 3% acrylic acid as an acrylic adhesive (Solid content: 15%) 24.3 parts: 1.2 parts of a 5% solution of estradiol in acetate, 0.2 part: sorbitan monolaurate: 0.25 parts, isopropyl myristate: 1.0 Parts, 0.05 parts of polyvinylpyrrolidone, 19 parts of ethyl acetate and 13 parts of ethanol were added as a crosslinking agent.
  • a patch was obtained in the same manner as in Example 1 except that the composition shown in Table 1 was changed.
  • Example 1 Example 2 Example 3 Example 4 Example 5 Example 6 Example 7 Example 8 Comparative Example 1 Comparative Example 2 Estradiol 1.2 1.2 0.8 1.2 1.2 1.8 1.2 1.2 1.2 1.2 Acrylic adhesive 72.8 85.3 74.1 73.7 73.7 82.7 72.8 78.3 72.8 92.8 Sorbitan monolaurate 5 2.5 5 5 5 5 5 5 Poly-polykishetylene monolaurate 5 5
  • Crosslinker 1 1 0.1 0.1 0.1 0.5 1 0.5 1 1 1 Blood drug concentration: 7 hours after application 4168 3802 3959 4103 3756 6432 3929 4005 2183 1343 (pg / ml): 24 hours after application 1938 1462 2505 2342 1625 2362 1618 2156 960 812

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une préparation adhésive qui comprend un support souple sur un côté duquel est formée une couche auto-adhésive contenant un médicament, un accélérateur d'absorption, et un adhésif autocollant. Dans cette préparation, i) le médicament est estradiol; ii) l'accélérateur d'absorption comprend une combinaison d'au moins soit un monolaurate de sorbitane soit un monolaurate de polyéthylèneglycol, et d'au moins un élément sélectionné parmi des esters d'acide gras supérieurs qui sont liquides à température ambiante et des hydrocarbures qui sont liquides à température ambiante; et iii) l'adhésif autocollant est un adhésif acrylique.
PCT/JP2001/009915 2000-11-17 2001-11-13 Preparation adhesive contenant estradiol WO2002040031A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
KR10-2003-7006318A KR100533493B1 (ko) 2000-11-17 2001-11-13 에스트라디올 함유 부착제
JP2002542404A JP3935839B2 (ja) 2000-11-17 2001-11-13 エストラジオール含有貼付剤
AU2002212763A AU2002212763A1 (en) 2000-11-17 2001-11-13 Adhesive preparation containing estradiol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-350657 2000-11-17
JP2000350657 2000-11-17

Publications (1)

Publication Number Publication Date
WO2002040031A1 true WO2002040031A1 (fr) 2002-05-23

Family

ID=18823846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/009915 WO2002040031A1 (fr) 2000-11-17 2001-11-13 Preparation adhesive contenant estradiol

Country Status (5)

Country Link
JP (1) JP3935839B2 (fr)
KR (1) KR100533493B1 (fr)
CN (1) CN1198621C (fr)
AU (1) AU2002212763A1 (fr)
WO (1) WO2002040031A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515617A (ja) * 2003-01-03 2006-06-01 ディーピーシー プロダクツ， インコーポレイテッド ギルソナイト由来薬学的送達組成物および方法
JP2019210440A (ja) * 2018-06-08 2019-12-12 株式会社日本触媒 粘着剤組成物及びその利用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0344326A (ja) * 1989-07-10 1991-02-26 Sekisui Chem Co Ltd 経皮吸収製剤
JPH0344327A (ja) * 1989-07-10 1991-02-26 Sekisui Chem Co Ltd 経皮吸収製剤
WO1996003131A1 (fr) * 1994-07-22 1996-02-08 Sekisui Kagaku Kogyo Kabushiki Kaisha Preparation se pretant a une absorption percutanee
JPH09100227A (ja) * 1989-09-08 1997-04-15 Cygnus Inc 経皮ドラッグデリバリーのための固体マトリックスシステム
JPH09315957A (ja) * 1996-05-28 1997-12-09 Hisamitsu Pharmaceut Co Inc 経皮治療用装置
WO2000064418A2 (fr) * 1999-04-22 2000-11-02 Lts Lohmann Therapie-Systeme Ag Systeme therapeutique transdermique a adhesifs de contact acryliques neutralises

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0344326A (ja) * 1989-07-10 1991-02-26 Sekisui Chem Co Ltd 経皮吸収製剤
JPH0344327A (ja) * 1989-07-10 1991-02-26 Sekisui Chem Co Ltd 経皮吸収製剤
JPH09100227A (ja) * 1989-09-08 1997-04-15 Cygnus Inc 経皮ドラッグデリバリーのための固体マトリックスシステム
WO1996003131A1 (fr) * 1994-07-22 1996-02-08 Sekisui Kagaku Kogyo Kabushiki Kaisha Preparation se pretant a une absorption percutanee
JPH09315957A (ja) * 1996-05-28 1997-12-09 Hisamitsu Pharmaceut Co Inc 経皮治療用装置
WO2000064418A2 (fr) * 1999-04-22 2000-11-02 Lts Lohmann Therapie-Systeme Ag Systeme therapeutique transdermique a adhesifs de contact acryliques neutralises

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515617A (ja) * 2003-01-03 2006-06-01 ディーピーシー プロダクツ， インコーポレイテッド ギルソナイト由来薬学的送達組成物および方法
JP2019210440A (ja) * 2018-06-08 2019-12-12 株式会社日本触媒 粘着剤組成物及びその利用
JP7112256B2 (ja) 2018-06-08 2022-08-03 株式会社日本触媒 粘着剤組成物及びその利用

Also Published As

Publication number Publication date
KR100533493B1 (ko) 2005-12-06
JP3935839B2 (ja) 2007-06-27
CN1198621C (zh) 2005-04-27
JPWO2002040031A1 (ja) 2004-03-18
CN1474695A (zh) 2004-02-11
AU2002212763A1 (en) 2002-05-27
KR20040011430A (ko) 2004-02-05

Similar Documents

Publication Publication Date Title
JP4660858B2 (ja) 経皮吸収型製剤
JP5016309B2 (ja) 医療用テープ剤
GB2273044A (en) Medicinal patches for percutaneous administration
US20060193900A1 (en) Pressure sensitive adhesive and patch
KR20070008676A (ko) 가교형 피부용 점착제
WO2001062254A1 (fr) Pieces contenant de la buprenorphine chlorhydrate
JPH06205839A (ja) 経皮投与型薬物用貼付剤
WO2003103641A1 (fr) Timbre
IE66144B1 (en) A percutanseous-administration-type pharmaceutical preparation of nitroglycerin
JP2017511174A (ja) 改善された適合性（ｃｏｍｐａｔｉｂｉｌｉｔｙ）および長い接着期間を有するオーバーパッチ（ｏｖｅｒ−ｐａｔｃｈ）、ならびに前記オーバーパッチを製造するための方法
JP5684441B2 (ja) インドメタシン含有貼付剤
JP2004504409A (ja) ポリアクリレートおよびポリアミン塩の２相接着剤マトリックスを含有する医療用接触接着性組成物
WO2002040031A1 (fr) Preparation adhesive contenant estradiol
JP4988080B2 (ja) 経皮吸収型製剤
JPH08143458A (ja) 経皮吸収貼付剤
WO2004066985A1 (fr) Materiau pour cataplasme aqueux mince
JP3046330B2 (ja) 貼付製剤
JP5226230B2 (ja) 貼付剤用粘着剤組成物及びその用途
JP3406188B2 (ja) 貼付剤
JP2005529150A (ja) 気管支拡張薬を有するマトリックスタイプパッチ
JP3226395B2 (ja) 経皮吸収貼付剤
JP4869583B2 (ja) 角質剥離が少ない貼付剤
JP2008101028A (ja) 経皮吸収型製剤
WO2021106782A1 (fr) Procédé améliorant la résistance de collage de couche d'adhésif pour timbre transdermique comprenant un ropinirole, et timbre transdermique de meilleure résistance de collage comprenant un ropinirole
CA2336704A1 (fr) Composition de trinitrate de glycerine, son procede de fabrication et son utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002542404

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020037006318

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018190901

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 1020037006318

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1020037006318

Country of ref document: KR